glp-1 receptor medications Agonists as Treatments for Type 2 Diabetes Best Med #2: GLP-1 Receptor

North Carolina eliminated GLP-1 coverage beginning October 2025 due to a budget stalemate in the legislature, but coverage was reinstated in December 2025, bringing the total number of states covering GLP-1s for obesity to 13 as of January 2026

Tirzepatide is a dual-acting medication that targets two specific hormone receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)

Use self-tracking to monitor your response to medication and diet

Patients with a history of pancreatitis or medullary thyroid cancer, or with a personal or family history of multiple endocrine neoplasia 2 (MEN2), are advised not to take these drugs